Alan Lau
5PUBLICATIONS
85CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 31, 2026
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.Juanita S Lopez, Kevin J Harrington, Seock-Ah Im
|Jan 15, 2026
Pathway for the Development of ATR Inhibitors in Pediatric Malignancies: An ACCELERATE Multistakeholder Analysis.Susanne A Gatz, Julia Glade-Bender, Andrew D J Pearson
|Feb 24, 2024
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.Elizabeth L Hardaker, Emilio Sanseviero, Ankur Karmokar
|Aug 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.Ankur Karmokar, Rebecca Sargeant, Adina M Hughes
|Aug 03, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.Violeta Serra, Anderson T Wang, Marta Castroviejo-Bermejo
Pageof 1
Frequent Collaborators
3 joint publications
Emma Dean
2 joint publications
Elaine Cadogan
2 joint publications
Adina Hughes
2 joint publications
Zena Wilson
1 joint publications
Anderson T Wang
1 joint publications
Marta Castroviejo-Bermejo
1 joint publications
Matthew G Krebs
1 joint publications
Marta Palafox
1 joint publications
Andrea Herencia-Ropero
1 joint publications
Zhongwu Lai
